Provectus Announces Acceptance of PV-10 Poster Presentations at SMR 2019 Congress
September 24, 2019 09:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10® in combination...